Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 9/20 | 0.38 |
| ▸ | MAOA | P21397 | 5/20 | 0.38 |
| ▸ | LPL | P06858 | 1/20 | 0.36 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17400963 | 0.83 | SLC6A4 (0.37) | APPSLC6A4MAOAMAOBTSHR | |
| SCHEMBL7423260 | 0.80 | NPC1 (0.39) | MAOAMAOBMAPK1L3MBTL1 | |
| SCHEMBL10053321 | 0.80 | MAOA (0.37) | APPSLC6A4MAOAMAOB | |
| SCHEMBL1775568 | 0.78 | NPC1 (0.37) | MAOAMAOBTSHRTDP1 | |
| SCHEMBL9273164 | 0.78 | BACE1 (0.40) | MAOAMAOBTSHRTDP1 | |
| SCHEMBL2040029 | 0.78 | ALDH1A1 (0.42) | MAOATDP1L3MBTL1 | |
| SCHEMBL573866 | 0.78 | MAOA (0.58) | MAOAMAOB | |
| SCHEMBL1773871 | 0.78 | APP (0.47) | APPMAOAMAOBTSHR | |
| SCHEMBL17835334 | 0.78 | NQO1 (0.50) | TSHRTDP1 | |
| SCHEMBL3224927 | 0.78 | MAOA (0.55) | MAOAMAOBMAPK1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7943748-B2 | Glucitol derivative, prodrug thereof and salt thereof, and therapeutic agent containing the same for diabetes | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-05-17 | — | — | US | disclosed |
| CN-1989132-B | Novel glucitol derivative, prodrug thereof, salt thereof, and therapeutic agent for diabetes containing the same | CHUGAI PHARMACEUTICAL CO LTD | 2010-06-09 | — | — | CN | disclosed |
| US-20080319047-A1 | Novel Glucitol Derivative, Prodrug Thereof And Salt Thereof, And Therapeutic Agent Containing The Same For Diabetes | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2008-12-25 | — | — | US | disclosed |
| EP-1803721-A1 | NOVEL GLUCITOL DERIVATIVE, PRODRUG THEREOF AND SALT THEREOF, AND THERAPEUTIC AGENT CONTAINING THE SAME FOR DIABETES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-07-04 | — | — | EP | disclosed |
| CN-1989132-A | Novel glucitol derivative, prodrug thereof, salt thereof, and therapeutic agent for diabetes containing the same | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2007-06-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080319047-A1 | Novel Glucitol Derivative, Prodrug Thereof And Salt Thereof, And Therapeutic Agent Containing The Same For Diabetes | SLC5A1, SLC5A2, GPR119 | APP 2896/4885SLC6A4 824/4885MAOA 4634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.